Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 Black Phoenix Black Phoenix +335.40%
#4 aPriori aPriori +133.73%
#5 Bedrock Bedrock +69.96%
#6 Cysic Cysic +48.18%
#7 Prom Prom +40.32%
#8 Playnance Playnance +34.95%
#9 COTI COTI +27.64%
#10 Bitway Bitway +26.68%
Coin of the day
Wrapped One Wrapped One
Settings
Language
ENGLISH
Currency
USD
Theme
Ember Therapeutics, Inc. Ember Therapeutics, Inc.

Ember Therapeutics, Inc.

EMBT
Rank in Stocks #42686
Ember Therapeutics, Inc. operates as a biopharmaceutical company currently in... Ember Therapeutics, Inc. operates as a biopharmaceutical company currently in its clinical development phase. Its core mission involves exploring the therapeutic applications of bone morphogenetic protein-7 (BMP-7) to engineer regenerative treatments. These innovative therapies are designed to alter the course of osteoarthritis, reverse insulin resistance, and inhibit or undo organ fibrosis in diseases such as chronic kidney disease and Alport's syndrome, alongside metabolic conditions like obesity and type 2 diabetes. Among its leading BMP-7-based drug candidates, MT-006 has successfully completed a Phase 2a clinical trial focused on osteoarthritis. Furthermore, MT-007, aimed at CKD and Alport syndrome; MT-008, specifically for Alport syndrome; and MT-009, targeting metabolic disease, have all concluded their preclinical trial phases. The company also maintains a substantial intellectual property portfolio, encompassing approximately 450 patents related to BMP-7, its associated protein families, various derivatives, novel delivery systems, specialized formulations, supporting clinical data, and materials produced under current good manufacturing practices. Ember Therapeutics, Inc. was established in 2010 and is headquartered in New York, New York.
Share Price
$0.0001
Last synced: 2026-02-06
Market Cap
$398.00
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Ember Therapeutics, Inc. (EMBT)

Category

Healthcare
P/E ratio for Ember Therapeutics, Inc. (EMBT)
P/E ratio as of 2026 TTM: 0
According to Ember Therapeutics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Ember Therapeutics, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.